Literature DB >> 7556552

Regional differences in responsiveness of adult CNS axons to grafts of cells expressing human neurotrophin 3.

M C Senut1, M H Tuszynski, H K Raymon, S T Suhr, N H Liou, K R Jones, L F Reichardt, F H Gage.   

Abstract

Neurotrophin 3 (NT3) belongs to the neurotrophin family, which also includes nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 4/5. NT3 mRNA is widely expressed in the rodent nervous system, but the physiological function of the native protein is still unclear. Genetically modified cell lines that produce physiological amounts of NT3 can provide a useful tool in the elucidation of the NT3 effects in the adult central nervous system (CNS). Genetically modified rat primary skin fibroblasts expressing and secreting human NT3 (hNT3) were prepared and characterized. In vitro, cell lines derived from different retroviral constructs expressed hNT3 mRNA, as determined by PCR and RNA blot analysis. Secretion of biologically active hNT3 was confirmed by specific elicitation of neurite outgrowth from cultured chick primary sympathetic and sensory neurons and from rat fetal locus coeruleus neurons in the presence of hNT3-producing cell conditioned media. In vivo, implanted fibroblasts survived well up to the maximal experimental time points of 6 weeks (brain) and 4 weeks (spinal cord) and continued to express hNT3 mRNA in vivo. As early as 2 weeks postgrafting, specific sprouting of host sensory neurites in response to hNT3-producing grafts was observed in the spinal cord. In contrast, hNT3-producing cerebral grafts did not induce a sprouting response different from that observed with control grafts. These findings establish the existence of a regionally different responsiveness of the CNS axons to local hNT3 overexpression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556552     DOI: 10.1006/exnr.1995.1064

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  8 in total

1.  Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury.

Authors:  R Grill; K Murai; A Blesch; F H Gage; M H Tuszynski
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

Review 2.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

3.  Gene transfer to the rodent placenta in situ. A new strategy for delivering gene products to the fetus.

Authors:  M C Senut; S T Suhr; F H Gage
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

4.  Integration and long distance axonal regeneration in the central nervous system from transplanted primitive neural stem cells.

Authors:  Jiagang Zhao; Woong Sun; Hyo Min Cho; Hong Ouyang; Wenlin Li; Ying Lin; Jiun Do; Liangfang Zhang; Sheng Ding; Yizhi Liu; Paul Lu; Kang Zhang
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

5.  Neurotrophins: potential therapeutic tools for the treatment of spinal cord injury.

Authors:  Edmund R Hollis; Mark H Tuszynski
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

6.  High content screening of cortical neurons identifies novel regulators of axon growth.

Authors:  Murray G Blackmore; Darcie L Moore; Robin P Smith; Jeffrey L Goldberg; John L Bixby; Vance P Lemmon
Journal:  Mol Cell Neurosci       Date:  2010-02-14       Impact factor: 4.314

7.  Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord.

Authors:  D M McTigue; P J Horner; B T Stokes; F H Gage
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

8.  Brain-derived neurotrophic factor gene-modified bone marrow mesenchymal stem cells.

Authors:  Zhong-Min Han; He-Mei Huang; Fei-Fei Wang
Journal:  Exp Ther Med       Date:  2014-12-08       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.